Last $15.22 USD
Change Today +0.04 / 0.26%
Volume 1.6M
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Snapshot

Open
$15.44
Previous Close
$15.18
Day High
$15.95
Day Low
$15.07
52 Week High
07/30/14 - $15.95
52 Week Low
11/13/13 - $8.95
Market Cap
2.2B
Average Volume 10 Days
1.1M
EPS TTM
$-1.89
Shares Outstanding
119.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (IRWD)

ironwood pharmaceuticals inc (IRWD) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (IRWD) Details

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company’s lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

534 Employees
Last Reported Date: 02/7/14
Founded in 1998

ironwood pharmaceuticals inc (IRWD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $360.9K
Chief Scientific Officer, President of Resear...
Total Annual Compensation: $376.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $366.6K
Compensation as of Fiscal Year 2013.

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals, Inc. Appoints Gina Consylman as Vice President, Corporate Controller and Chief Accounting Officer

Effective June 23, 2014, Ironwood Pharmaceuticals, Inc. appointed Gina Consylman, 42, as its Vice President, Corporate Controller and Chief Accounting Officer. Prior to joining the Company, Ms. Consylman served as Vice President, Corporate Controller and Principal Accounting Officer of Analogic Corporation.

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:00 PM

Ironwood Pharmaceuticals, Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-11-2014 02:00 PM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Peter M. Hecht, Co-Founder, Chief Executive Officer and Director.

Ironwood Pharmaceuticals, Inc. Appoints Douglas Williams to Board of Directors

Ironwood Pharmaceuticals, Inc. announced the appointment of Douglas Williams, Ph.D., to its board of directors. Dr. Williams currently serves as executive vice president, research and development for Biogen Idec Inc. and was previously chief executive officer of ZymoGenetics, Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $15.22 USD +0.04

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $4.59 USD +0.09
Nektar Therapeutics $11.01 USD +0.01
Progenics Pharmaceuticals Inc $5.03 USD 0.00
Sucampo Pharmaceuticals Inc $6.16 USD +0.08
Theravance Inc $21.95 USD +0.16
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.5x
Price/Book 11.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.